Optune Mya is not approved for brain metastases from non-small cell lung cancer in topline regulatory results
The FDA issued a Not Approvable Letter for Novocure's Optune Mya for treating brain metastases from non-small cell lung cancer, citing uncertainty about clinical benefit. The FDA did not raise safety concerns. Novocure plans to meet with the FDA to explore approval options.
How this was made

The 30-second read
Why it matters
The regulatory decision eliminates immediate market entry for this indication, likely depressing NVCR's share price and prompting investors to reassess the company's pipeline valuation.
Market read
A primary regulatory denial for a key oncology device, directly affecting Novocure's growth prospects.
What to watch
Potential for off-label use or alternative regulatory pathways that could mitigate impact.
Background
Novocure announced the FDA's Not Approvable Letter for its Optune Mya system targeting brain metastases from NSCLC. The device uses Tumor Treating Fields (TTFields). No safety concerns were raised, but efficacy data were insufficient.
Ticker impact
FDA issued a Not Approvable Letter for Novocure's Optune Mya device for brain metastases from NSCLC, halting approval.
likely downward pressure as the market prices in the regulatory setback
Regulatory denial is a material event that directly affects the company's product pipeline and future sales.
Market effects
May weigh on other TTFields or medical device companies awaiting FDA decisions.
Limited to US biotech/medical device sector.
Minimal beyond the niche oncology device market.
Counterpoint
If Novocure can address FDA concerns without additional trials, a rapid resubmission could limit downside.
Key entities
- CompanyNovocure
Developer of Optune Mya TTFields device, listed on NASDAQ as NVCR.
- RegulatorFDA
U.S. Food and Drug Administration issuing the Not Approvable Letter.

